From The Editor

  1. BIO 2026: China, AI, And FDA 7/6/2026

    What happened at BIO? This selected coverage from the BIO 2026 meeting in San Diego includes highlights from panels on China, AI, and an FDA Town Hall.

  2. Where Are They Now? Life Science Cares 2/27/2026

    Life Science Cares, an industry philanthropic organization, turns 10 in April. Now in five cities and Switzerland, the organization remains focused on fighting poverty.

  3. On The Road: The Business Of Biotech In San Francisco For JPM2026 2/3/2026

    The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and reportage from a selection of interviews, events, and company presentations.

  4. Galien Forum: CEOs Talk FDA, China, Funding Sources 11/25/2025

    Part two of a two-part series covering FDA Commissioner Makary’s comments at the Galien Forum on October 30, plus coverage of a CEO roundtable on FDA, China, and funding.

  5. Makary Talks Faster Drug Reviews, 'Continuous Trials,' DTC Ads 10/31/2025

    Part one of a two-part series on FDA Commissioner Martin Makary, M.D.'s comments at the Gailen Forum in New York City on October 30, 2025.

  6. Reading The FDA Tea Leaves On Psychedelics 10/17/2025

    MAPS founder Rick Doblin accused the FDA of changing the goal posts after Lykos's MDMA Complete Response Letter was released, and offered insights for other psychedelic developers.

  7. Partnering To Commercialize Radiopharmaceuticals 10/9/2025

    For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new products.

  8. From Scientific Discovery To Next Generation Treatments For Obesity 7/31/2025

    Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver products that improve upon currently available treatments for obesity.

  9. Epic Bio's Big Swing In Epigenetic Editing 7/11/2025

    Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about epigenetic editing, working with the FDA, using AI for clinical endpoints, and more.

  10. BIO2025: Sanofi R&D, FDA's Martin Makary, Paying For New Therapies 6/20/2025

    BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I attended.